• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Bristol-Myers Squibb Company - Articles and news items

renal-cell-cancer

NICE recommends ‘breakthrough’ drug nivolumab for advanced renal cell cancer

Industry news / 21 October 2016 / Niamh Louise Marriott, Digital Content Producer

Nivolumab is an intravenous drug, a form of immunotherapy that works by harnessing the power of the patient’s own immune system to destroy the cancer cells…

bristol-myers-sqibb-cdf

NICE says CDF case for nivolumab to treat lung cancer is not clear cut

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients in the treatment of non small-cell lung cancer…

scotland-nhs-lung-cancer

Scotland speeds ahead to deliver breakthrough immunotherapy to lung cancer patients 

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

This recommendation means that patients in Scotland will become the first in the UK to be treated with nivolumab on the NHS…

head and neck cancer

‘Game-changing’ immunotherapy doubles head and neck cancer survival

Industry news, Z Homepage promo / 10 October 2016 / Niamh Louise Marriott, Digital Content Producer

An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer…

collabs

Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

Bristol-Myers’ Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy…

smc

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

cormorant pharmaceuticals

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

The acquisition gives Bristol-Myers Squibb full rights to Cormorant Pharmaceuticals’ HuMax-IL8 antibody programme…

enadenotucirev

BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients…

sickle cell disease

BMS in sickle cell partnership to help treat Angolan children

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

The Angola Sickle Cell Initiative and Bristol-Myers Squibb are teaming up to provide children with sickle cell disease in Angola with Droxia…

nivolumab

NICE recommends nivolumab + ipilimumab for advanced melanoma

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

The NHS will receive a discount on the combination treatment agreed between Bristol-Myers Squibb and the Department of Health…

Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research

Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research

Industry news / 8 June 2016 / Mandy Parrett, Editorial Assistant

Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.

PharmaMar initiates a phase III ATLANTIS study in patients with small cell lung cancer

BMS and MD Anderson in lung cancer research collaboration

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

BMS and MD Anderson are to collaborate to evaluate innovative strategies for the use of Opdivo and Yervoy to treat lung cancer patients…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +